{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:23:45Z","timestamp":1788009825631,"version":"build-2784847793"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00415-025-13249-z","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T04:58:50Z","timestamp":1753073930000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Serum GFAP and NFL as biomarkers for disease activity, severity and disability in NMOSD"],"prefix":"10.1007","volume":"272","author":[{"given":"Rui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongren","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyao","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7637-1305","authenticated-orcid":false,"given":"Hongyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"issue":"2","key":"13249_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177\u2013189. https:\/\/doi.org\/10.1212\/WNL.0000000000001729","journal-title":"Neurology"},{"issue":"7","key":"13249_CR2","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1177\/1352458515620934","volume":"22","author":"BA Cree","year":"2016","unstructured":"Cree BA, Bennett JL, Sheehan M et al (2016) Placebo-controlled study in neuromyelitis optica-ethical and design considerations. Mult Scler 22(7):862\u2013872. https:\/\/doi.org\/10.1177\/1352458515620934","journal-title":"Mult Scler"},{"issue":"6","key":"13249_CR3","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00401-013-1116-7","volume":"125","author":"T Misu","year":"2013","unstructured":"Misu T, H\u00f6ftberger R, Fujihara K et al (2013) Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol 125(6):815\u2013827. https:\/\/doi.org\/10.1007\/s00401-013-1116-7","journal-title":"Acta Neuropathol"},{"key":"13249_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.brainres.2014.12.027","volume":"1600","author":"A Petzold","year":"2015","unstructured":"Petzold A (2015) Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease. Brain Res 1600:17\u201331. https:\/\/doi.org\/10.1016\/j.brainres.2014.12.027","journal-title":"Brain Res"},{"issue":"3","key":"13249_CR5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1212\/WNL.0b013e3181e2414b","volume":"75","author":"R Takano","year":"2010","unstructured":"Takano R, Misu T, Takahashi T et al (2010) Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 75(3):208\u2013216. https:\/\/doi.org\/10.1212\/WNL.0b013e3181e2414b","journal-title":"Neurology"},{"issue":"5","key":"13249_CR6","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1136\/jnnp.2008.150698","volume":"80","author":"T Misu","year":"2009","unstructured":"Misu T, Takano R, Fujihara K et al (2009) Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry 80(5):575\u2013577. https:\/\/doi.org\/10.1136\/jnnp.2008.150698","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"13249_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/1744666X.2023.2148657","volume":"19","author":"P Schindler","year":"2023","unstructured":"Schindler P, Aktas O, Ringelstein M et al (2023) Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review. Expert Rev Clin Immunol 19(1):71\u201391. https:\/\/doi.org\/10.1080\/1744666X.2023.2148657","journal-title":"Expert Rev Clin Immunol"},{"key":"13249_CR8","doi-asserted-by":"publisher","first-page":"647618","DOI":"10.3389\/fimmu.2021.647618","volume":"12","author":"X Chang","year":"2021","unstructured":"Chang X, Huang W, Wang L et al (2021) Serum neurofilament light and GFAP are associated with disease severity in inflammatory disorders with aquaporin-4 or myelin oligodendrocyte glycoprotein antibodies. Front Immunol 12:647618. https:\/\/doi.org\/10.3389\/fimmu.2021.647618","journal-title":"Front Immunol"},{"issue":"13","key":"13249_CR9","doi-asserted-by":"publisher","first-page":"e1299","DOI":"10.1212\/WNL.0000000000008160","volume":"93","author":"M Watanabe","year":"2019","unstructured":"Watanabe M, Nakamura Y, Michalak Z et al (2019) Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology 93(13):e1299\u2013e1311. https:\/\/doi.org\/10.1212\/WNL.0000000000008160","journal-title":"Neurology"},{"issue":"5","key":"13249_CR10","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ana.26067","volume":"89","author":"O Aktas","year":"2021","unstructured":"Aktas O, Smith MA, Rees WA et al (2021) Serum glial fibrillary acidic protein: a neuromyelitis optica spectrum disorder biomarker. Ann Neurol 89(5):895\u2013910. https:\/\/doi.org\/10.1002\/ana.26067","journal-title":"Ann Neurol"},{"issue":"1","key":"13249_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12974-021-02138-7","volume":"18","author":"P Schindler","year":"2021","unstructured":"Schindler P, Grittner U, Oechtering J et al (2021) Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. J Neuroinflammation 18(1):105. https:\/\/doi.org\/10.1186\/s12974-021-02138-7","journal-title":"J Neuroinflammation"},{"issue":"1","key":"13249_CR12","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s00415-022-11364-9","volume":"270","author":"S Yang","year":"2023","unstructured":"Yang S, Zhang C, Zhang TX et al (2023) A real-world study of interleukin-6 receptor blockade in patients with neuromyelitis optica spectrum disorder. J Neurol 270(1):348\u2013356. https:\/\/doi.org\/10.1007\/s00415-022-11364-9","journal-title":"J Neurol"},{"issue":"5","key":"13249_CR13","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","volume":"20","author":"M Khalil","year":"2024","unstructured":"Khalil M, Teunissen CE, Lehmann S et al (2024) Neurofilaments as biomarkers in neurological disorders - towards clinical application. Nat Rev Neurol 20(5):269\u2013287. https:\/\/doi.org\/10.1038\/s41582-024-00955-x","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"13249_CR14","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","volume":"21","author":"P Benkert","year":"2022","unstructured":"Benkert P, Meier S, Schaedelin S et al (2022) Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol 21(3):246\u2013257. https:\/\/doi.org\/10.1016\/S1474-4422(22)00009-6","journal-title":"Lancet Neurol"},{"issue":"2","key":"13249_CR15","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1001\/jamaneurol.2024.4400","volume":"82","author":"SH Kim","year":"2025","unstructured":"Kim SH, Gomes ABAGR, Schindler P et al (2025) Blood-based biomarkers for identifying disease activity in AQP4-IgG-positive neuromyelitis optica spectrum disorder. JAMA Neurol 82(2):168\u2013175. https:\/\/doi.org\/10.1001\/jamaneurol.2024.4400","journal-title":"JAMA Neurol"},{"issue":"7","key":"13249_CR16","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1007\/s00415-024-12382-5","volume":"271","author":"R Wang","year":"2024","unstructured":"Wang R, Sun D, Wang X et al (2024) Correlation between severe attacks and serum aquaporin-4 antibody titer in neuromyelitis optica spectrum disorder. J Neurol 271(7):4503\u20134512. https:\/\/doi.org\/10.1007\/s00415-024-12382-5","journal-title":"J Neurol"},{"issue":"1","key":"13249_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/ene.13186","volume":"24","author":"H Chen","year":"2017","unstructured":"Chen H, Qiu W, Zhang Q et al (2017) Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder. Eur J Neurol 24(1):219\u2013226. https:\/\/doi.org\/10.1111\/ene.13186","journal-title":"Eur J Neurol"},{"issue":"10","key":"13249_CR18","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","volume":"54","author":"J Kuhle","year":"2016","unstructured":"Kuhle J, Barro C, Andreasson U et al (2016) Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 54(10):1655\u20131661. https:\/\/doi.org\/10.1515\/cclm-2015-1195","journal-title":"Clin Chem Lab Med"},{"issue":"5","key":"13249_CR19","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/jnc.15478","volume":"159","author":"C Liu","year":"2021","unstructured":"Liu C, Lu Y, Wang J et al (2021) Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: a cohort study. J Neurochem 159(5):913\u2013922. https:\/\/doi.org\/10.1111\/jnc.15478","journal-title":"J Neurochem"},{"issue":"4","key":"13249_CR20","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1177\/13524585211024978","volume":"28","author":"H Kim","year":"2022","unstructured":"Kim H, Lee EJ, Kim S et al (2022) Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder. Mult Scler 28(4):512\u2013521. https:\/\/doi.org\/10.1177\/13524585211024978","journal-title":"Mult Scler"},{"issue":"4","key":"13249_CR21","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1177\/13524585211028831","volume":"28","author":"L Aly","year":"2022","unstructured":"Aly L, Strau\u00df EM, Feucht N et al (2022) Optical coherence tomography angiography indicates subclinical retinal disease in neuromyelitis optica spectrum disorders. Mult Scler 28(4):522\u2013531. https:\/\/doi.org\/10.1177\/13524585211028831","journal-title":"Mult Scler"},{"issue":"3","key":"13249_CR22","doi-asserted-by":"publisher","first-page":"e708","DOI":"10.1212\/NXI.0000000000000708","volume":"7","author":"H Kim","year":"2020","unstructured":"Kim H, Lee EJ, Kim S et al (2020) Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease. Neurol Neuroimmunol Neuroinflamm 7(3):e708. https:\/\/doi.org\/10.1212\/NXI.0000000000000708","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"13249_CR23","doi-asserted-by":"publisher","first-page":"e224","DOI":"10.1212\/NXI.0000000000000224","volume":"3","author":"RE Ventura","year":"2016","unstructured":"Ventura RE, Kister I, Chung S, Babb JS, Shepherd TM (2016) Cervical spinal cord atrophy in NMOSD without a history of myelitis or MRI-visible lesions. Neurol Neuroimmunol Neuroinflamm 3(3):e224. https:\/\/doi.org\/10.1212\/NXI.0000000000000224","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"13249_CR24","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1212\/NXI.0000000000000334","volume":"4","author":"FC Oertel","year":"2017","unstructured":"Oertel FC, Kuchling J, Zimmermann H et al (2017) Microstructural visual system changes in AQP4-antibody-seropositive NMOSD. Neurol Neuroimmunol Neuroinflamm 4(3):e334. https:\/\/doi.org\/10.1212\/NXI.0000000000000334","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"13249_CR25","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.1212\/WNL.0000000000008684","volume":"94","author":"M Ringelstein","year":"2020","unstructured":"Ringelstein M, Harmel J, Zimmermann H et al (2020) Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. Neurology 94(4):e407\u2013e418. https:\/\/doi.org\/10.1212\/WNL.0000000000008684","journal-title":"Neurology"},{"issue":"6","key":"13249_CR26","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/acn3.51070","volume":"7","author":"EJ Lee","year":"2020","unstructured":"Lee EJ, Lim YM, Kim S et al (2020) Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases. Ann Clin Transl Neurol 7(6):992\u20131001. https:\/\/doi.org\/10.1002\/acn3.51070","journal-title":"Ann Clin Transl Neurol"},{"issue":"6","key":"13249_CR27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1177\/1352458519840757","volume":"26","author":"JW Hyun","year":"2020","unstructured":"Hyun JW, Kim Y, Kim G, Kim SH, Kim HJ (2020) Longitudinal analysis of serum neurofilament light chain: a potential therapeutic monitoring biomarker for multiple sclerosis. Mult Scler 26(6):659\u2013667. https:\/\/doi.org\/10.1177\/1352458519840757","journal-title":"Mult Scler"},{"issue":"1","key":"13249_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.bbrc.2010.02.157","volume":"394","author":"M Kinoshita","year":"2010","unstructured":"Kinoshita M, Nakatsuji Y, Kimura T et al (2010) Anti-aquaporin- 4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells. Biochem Biophys Res Commun 394(1):205\u2013210. https:\/\/doi.org\/10.1016\/j.bbrc.2010.02.157","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"13249_CR29","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/WCO.0000000000000694","volume":"32","author":"K Fujihara","year":"2019","unstructured":"Fujihara K (2019) Neuromyelitis optica spectrum disorders: still evolving and broadening. Curr Opin Neurol 32(3):385\u2013394. https:\/\/doi.org\/10.1097\/WCO.0000000000000694","journal-title":"Curr Opin Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13249-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13249-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13249-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T02:39:29Z","timestamp":1756607969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13249-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["13249"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13249-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have any conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The Medical Ethics Committee of West China Hospital, Sichuan University approved the study, and all participants provided informed consent prior to their inclusion in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"521"}}